Sodium bicarbonate

Identification

Name
Sodium bicarbonate
Accession Number
DB01390
Type
Small Molecule
Groups
Approved
Description

Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.

Structure
Thumb
Synonyms
  • Baking soda
  • Bicarbonate of soda
  • Carbonic acid monosodium salt
  • e 500
  • e-500
  • e500
  • NaHCO3
  • Natriumhydrogenkarbonat
  • Sodium acid carbonate
  • Sodium bicarbonate
  • Sodium hydrogen carbonate
  • Sodium hydrogencarbonate
External IDs
B1654 / E-500(II) / INS NO.500(II) / INS-500(II)
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
800 Sodium Bicarbonate PowderPowder, for solution650 gHemodialysisBaxter Laboratories1988-12-31Not applicableCanada
BibagPowder, for solution650 gHemodialysisFresenius Medical Care Deutchland Gmbh2009-12-10Not applicableCanada
Bicarb Hemodial Conc 81.25gm/lLiquid81.25 gHemodialysisBicarbolyte Corporation1986-12-311998-06-08Canada
Bicarbolyte Bicar Hemodialysis ConcLiquid72 gHemodialysisBicarbolyte Corporation1986-12-311998-06-08Canada
Bicarbonate Conc Mb-330 Pwr 650mg/pckPowder650 gHemodialysisRenal Systems, Division Of Minntech Corp.1985-12-311998-11-02Canada
Bicarbonate Concentrate 4105Liquid80.68 gHemodialysisBaxter Laboratories1988-12-312002-08-01Canada
Bicarbonate Concentrate B38Solution80.7 gHemodialysisChief Medical Supplies Ltd2005-07-04Not applicableCanada
Bicarbonate Concentrate D17000Solution81.3 gHemodialysisBaxter Laboratories1986-12-31Not applicableCanada
BicartPowder720 gHemodialysisBaxter Laboratories2013-09-26Not applicableCanada
BicartPowder650 gHemodialysisBaxter Laboratories1990-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sodium BicarbonateInjection, solution84 mg/mLIntravenousGeneral Injectables & Vaccines2010-08-01Not applicableUs
Sodium BicarbonateInjection, solution84 mg/mLIntravenousHospira, Inc.2006-05-18Not applicableUs
Sodium BicarbonateInjection84 mg/mLIntravenousInternational Medication Systems, Limited2000-06-01Not applicableUs
Sodium BicarbonateInjection, solution42 mg/mLIntravenousHospira, Inc.2017-01-012017-11-09Us
Sodium BicarbonateInjection, solution75 mg/mLIntravenousHospira, Inc.2006-05-18Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
After Bite KidsLiquid5 g/100gTopicalTender Corporation2014-11-26Not applicableUs
After Bite SensitiveLiquid5 g/100gTopicalTender Corporation2014-11-26Not applicableUs
After Bite the Itch EraserLiquid50 mg/mLTopicalTender Corporation2014-09-02Not applicableUs
After Bite The Itch Eraser KIDSLiquid5 g/100gTopicalTender Corporation2014-11-262016-10-29Us
Anti-EmpachoLiquid525 mg/15mLOralMenper Distributors2012-02-21Not applicableUs
Arm and Hammer Baking SodaPowder, for solution1 g/gOralChurch & Dwight Company, Inc.2000-01-01Not applicableUs
Assured Bug Bite ReliefLiquid5 g/100gTopicalShanghai Weierya Daily Chemicals Factory2015-11-10Not applicableUs
Baking Soda USPPowder100 %OralRegal Pharms, Division Of Bradcan Corporation1987-12-311996-12-16Canada
Brioschi Effervescent AntacidGranule, effervescent1.02 g/5gOralNeobourne Pharma Lp2015-06-30Not applicableUs
Brioschi Effervescent Antacid - 1.8gm/6gmGranule, effervescent1.8 gOralBrioschi, Inc.1998-05-142003-02-14Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Assured Bug Bite ReliefLiquid5 g/100gTopicalShanghai Weierya Daily Chemicals Factory2015-11-10Not applicableUs
NeutInjection, solution.2 g/5mLIntravenousGeneral Injectables & Vaccines2014-07-31Not applicableUs
Neut Sodium BicarbonateInjection, solution.2 g/5mLIntravenousHospira, Inc.2005-08-22Not applicableUs
Neut Sodium BicarbonateInjection, solution.2 g/5mLIntravenousCardinal Health2005-08-22Not applicableUs
Premier Value Sodium BicarbonatePowder1000 mg/gOralChain Drug Consortium2017-10-27Not applicableUs
Sodium BicarbonateInjection84 mg/mLParenteralAmphastar Pharmaceuticals, Inc.2000-06-012016-12-06Us
Sodium BicarbonateInjection, solution84 mg/mLIntravenousA S Medication Solutions1985-04-18Not applicableUs
Sodium BicarbonateInjection, solution84 mg/mLIntravenousRemedy Repack2015-03-072016-03-29Us
Sodium BicarbonateInjection, solution42 mg/mLIntravenousHospira, Inc.1984-01-27Not applicableUs
Sodium BicarbonateTablet650 mg/1OralCardinal Health2011-06-06Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Accusol 35 K0Sodium bicarbonate (12.9 g) + Calcium Chloride (0.343 g) + Magnesium chloride (0.136 g) + Sodium Chloride (7.66 g)SolutionHemodialysisChief Medical Supplies Ltd2007-10-31Not applicableCanada
Accusol 35 K2Sodium bicarbonate (12.9 g) + Calcium Chloride (0.343 g) + D-glucose (1.33 g) + Magnesium chloride (0.136 g) + Potassium Chloride (0.199 g) + Sodium Chloride (7.66 g)SolutionHemodialysisChief Medical Supplies LtdNot applicableNot applicableCanada
Accusol 35 K4Sodium bicarbonate (12.9 g) + Calcium Chloride (0.343 g) + D-glucose (1.33 g) + Magnesium chloride (0.136 g) + Potassium Chloride (0.398 g) + Sodium Chloride (7.66 g)SolutionHemodialysisChief Medical Supplies Ltd2007-10-31Not applicableCanada
Alka SeltzerSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)Tablet, effervescentOralSalimex, S.A.2012-10-10Not applicableUs
Alka SeltzerSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)Tablet, effervescentOralSalimex, S.A.2012-10-10Not applicableUs
Alka Seltzer EvtSodium bicarbonate (1.916 g) + Acetylsalicylic acid (325 mg) + Citric Acid (1 g)Tablet, effervescentOralMiles Inc. Pharmaceutical Division1977-12-311996-09-09Canada
Alka Seltzer FlavouredSodium bicarbonate (1.71 g) + Acetylsalicylic acid (325 mg) + Citric Acid (1.22 g)Tablet, effervescentOralMiles Inc. Pharmaceutical Division1986-12-311996-09-09Canada
Alka Seltzer OriginalSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)TabletOralNavajo Manuracturing Company2016-09-16Not applicableUs
Alka-SeltzerSodium bicarbonate (1916 mg) + Acetylsalicylic acid (325 mg) + Citric Acid (1000 mg)Tablet, effervescentOralBayer1995-12-31Not applicableCanada
Alka-SeltzerSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)Tablet, effervescentOralLil' Drug Store Products, Inc.2000-01-01Not applicableUs
Categories
UNII
8MDF5V39QO
CAS number
144-55-8
Weight
Average: 84.0066
Monoisotopic: 83.982338573
Chemical Formula
CHNaO3
InChI Key
UIIMBOGNXHQVGW-UHFFFAOYSA-M
InChI
InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
IUPAC Name
sodium hydrogen carbonate
SMILES
[Na+].OC([O-])=O

Pharmacology

Indication

Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.

Structured Indications
Pharmacodynamics

Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.

Mechanism of action

Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]

TargetActionsOrganism
AHydrogen ions
neutralizer
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium bicarbonate.Approved, Vet Approved
FlecainideSodium bicarbonate may decrease the arrhythmogenic activities of Flecainide.Approved, Withdrawn
LithiumSodium bicarbonate may increase the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.Approved
Food Interactions
Not Available

References

Synthesis Reference

Alan B. Gancy, Rustom P. Poncha, "Production of low bulk density product from sodium bicarbonate by the use of an inert gas stream." U.S. Patent US3984527, issued August, 1922.

US3984527
General References
Not Available
External Links
KEGG Drug
D01203
KEGG Compound
C12603
PubChem Compound
516892
PubChem Substance
46507049
ChemSpider
8609
ChEBI
32139
ChEMBL
CHEMBL1353
Therapeutic Targets Database
DAP000128
PharmGKB
PA451375
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sodium_bicarbonate
ATC Codes
B05XA02 — Sodium bicarbonateB05CB04 — Sodium bicarbonate
AHFS Codes
  • 40:08.00 — Alkalinizing Agents
  • 56:04.00 — Antacids and Adsorbents
  • 40:34.00* — Hemodialysis Solution
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceTransplantation, Kidney1
0CompletedTreatmentPulmonary Ventilation1
0Not Yet RecruitingTreatmentEdema of the cerebrum / Saline Solution, Hypertonic1
1Active Not RecruitingOtherHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionChronic Kidney Disease (CKD)1
1CompletedTreatmentAcid Reflux / Gastro Oesophageal Reflux Disease1
1CompletedTreatmentGastric Emptying / Healthy Volunteers1
1CompletedTreatmentHeartburn1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentNeoplasms, Malignant1
1RecruitingTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis / Sickle Cell Disorders1
1TerminatedSupportive CareCancers / Malignancies, Hematologic / Malignant Lymphomas / Malignant Solid Tumours / Multiple Myeloma (MM) / Neoplasms Metastasis / Pain / Tumors / Unresectable Malignant Neoplasm1
1Unknown StatusDiagnosticAdjunct to general anesthesia therapy1
1, 2Unknown StatusTreatmentPneumonia1
2CompletedOtherBowel preparation therapy1
2CompletedPreventionCardiac Surgery and Cardiopulmonary Bypass1
2CompletedPreventionContrast Induced Nephropathy (CIN)2
2CompletedPreventionKidney Injury1
2CompletedPreventionRadiographic Contrast Agent Nephropathy1
2CompletedTreatmentCardiac Arrest / Metabolic Acidosis1
2CompletedTreatmentImpaired Renal Function / Oliguria / Systemic Inflammatory Response Syndrome (SIRS)1
2Not Yet RecruitingDiagnosticKidney Transplant; Complications1
2RecruitingTreatmentAcute Kidney Injury (AKI) / Congenital Heart Disease (CHD)1
2RecruitingTreatmentAnaesthesia therapy / Local Infiltration1
2RecruitingTreatmentChronic Kidney Disease (CKD)1
2TerminatedTreatmentAcute Kidney Injury (AKI)1
2, 3CompletedPreventionContrast Induced Nephropathy (CIN)1
2, 3CompletedTreatmentChronic Kidney Disease (CKD)1
2, 3RecruitingTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis1
2, 3TerminatedPreventionCardiopulmonary Bypass / Surgery, Cardiac1
2, 3Unknown StatusDiagnosticDetection of the Correct Position of Intravenous Line1
2, 3Unknown StatusDiagnosticDrug Extravasation / Infiltration1
3Active Not RecruitingTreatmentMyocardial Injury After Noncardiac Surgery (MINS)1
3CompletedNot AvailableBowel Preparation for Colonoscopy1
3CompletedNot AvailableColonoscopy1
3CompletedNot AvailableContrast Induced Nephropathy (CIN) / Kidney Diseases1
3CompletedNot AvailableGastric Acid / Human Experimentation2
3CompletedNot AvailableIntragastric Acidity1
3CompletedNot AvailableLocal Anesthesia2
3CompletedDiagnosticBowel Preparation for Colonoscopy1
3CompletedDiagnosticBowel Preparation, Efficacy, Tolerability, Safety1
3CompletedPreventionChronic Kidney Disease (CKD)1
3CompletedPreventionRenal Failure1
3CompletedSupportive CareColon Adenomas / Colorectal Cancers1
3CompletedTreatmentCataracts2
3CompletedTreatmentColonoscopy1
3CompletedTreatmentHuman Experimentation1
3CompletedTreatmentMalignant Neoplasm of Colon1
3CompletedTreatmentOccasional Constipation1
3CompletedTreatmentReflux, Gastroesophageal1
3RecruitingOtherDigestive System Diseases1
3RecruitingPreventionAcute Kidney Injury (AKI) / Contrast media reaction1
3RecruitingTreatmentHealthy Volunteers1
3RecruitingTreatmentMetabolic Acidosis1
3TerminatedPreventionContrast Induced Kidney Injury1
3TerminatedPreventionHypopharynx Cancer / Oropharynx Cancers1
3Unknown StatusDiagnosticColonoscopy1
3Unknown StatusPreventionAcute Renal Failure (ARF)1
3Unknown StatusPreventionChronic Kidney Disease (CKD)1
3Unknown StatusPreventionKidney Failures, Acute1
4Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Diabetic Kidney Disease / Diabetic Nephropathies1
4CompletedNot AvailableColonoscopy1
4CompletedNot AvailableNormal Healthy Subject Population1
4CompletedPreventionContrast Induced Acute Kidney Injury1
4CompletedPreventionContrast Induced Nephropathy (CIN)2
4CompletedPreventionContrast media reaction / Kidney Diseases1
4CompletedPreventionEmergent Coronary Procedure1
4CompletedPreventionMarginal Ulcers1
4CompletedPreventionProphylaxis of Pulmonary embolism / Radiographic Contrast Agent Nephropathy1
4CompletedPreventionProphylaxis of Contrast-induced nephropathy1
4CompletedSupportive CareEnd-Stage Renal Disease (ESRD)1
4CompletedSupportive CarePain1
4CompletedTreatmentColonoscopy2
4CompletedTreatmentContrast Induced Nephropathy (CIN)1
4CompletedTreatmentErosive Esophagitis(EE)1
4CompletedTreatmentHeartburn1
4CompletedTreatmentMalignant Neoplasm of Colon1
4CompletedTreatmentPreparation for Colonoscopy1
4Enrolling by InvitationPreventionOral Mucositis1
4Enrolling by InvitationTreatmentLocal Anesthesia1
4Not Yet RecruitingDiagnosticBowel Preparation Solutions1
4Not Yet RecruitingHealth Services ResearchColorectal Cancers1
4RecruitingDiagnosticAnatomic renal artery stenosis / Chronic Kidney Disease (CKD) / Prophylaxis of Pulmonary embolism / Pulmonary Cancer1
4RecruitingPreventionAcute Kidney Injury (AKI)1
4RecruitingPreventionAcute Kidney Injury (AKI) / Aortic Valve Disorder / Chronic Kidney Disease (CKD) / Contrast Induced Nephropathy (CIN)1
4RecruitingTreatmentSubjets Requiring a Colonoscopy1
4RecruitingTreatmentVaricosities of the great saphenous vein1
4TerminatedPreventionContrast Media / Kidney Failures, Acute1
4Unknown StatusHealth Services ResearchColonoscopy1
4Unknown StatusTreatmentContrast Induced Nephropathy (CIN)1
4Unknown StatusTreatmentSudden Cardiac Arrest1
Not AvailableActive Not RecruitingDiagnosticDiabetes Mellitus (DM)1
Not AvailableCompletedNot AvailableEffectiveness of SMS to Fix PC Interval1
Not AvailableCompletedNot AvailableSpinal Cord Injuries (SCI)1
Not AvailableCompletedNot AvailableThe Timing of Bowel Preparation in Outpatient Colonoscopy1
Not AvailableCompletedPreventionAcute Kidney Injury (AKI)1
Not AvailableCompletedPreventionAcute Renal Failure Contrast Nephropathy1
Not AvailableCompletedPreventionContrast Induced Nephropathy (CIN)1
Not AvailableCompletedPreventionDysglycaemia / Insulin Resistance / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentCardiac Arrest1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis1
Not AvailableCompletedTreatmentHepatic Encephalopathy / Liver Cirrhosis / Portosystemic Encephalopathy / PSE1
Not AvailableCompletedTreatmentOral Hygiene1
Not AvailableNot Yet RecruitingTreatmentAsymptomatic Hyperuricemia / Gout Acute1
Not AvailableNot Yet RecruitingTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis1
Not AvailableRecruitingDiagnosticColonoscopy1
Not AvailableRecruitingHealth Services ResearchAcute Kidney Injury (AKI)1
Not AvailableRecruitingScreeningColonoscopy1
Not AvailableRecruitingTreatmentChronic Renal Insufficiency / Diabetes Mellitus (DM)1
Not AvailableRecruitingTreatmentHealthy Volunteers1
Not AvailableTerminatedPreventionContrast Induced Nephropathy (CIN)1
Not AvailableTerminatedSupportive CareNeoplasm Related Pain (Acute) (Chronic)1
Not AvailableUnknown StatusDiagnosticBowel Preparation for Colonoscopy1
Not AvailableUnknown StatusDiagnosticPreserving Kidney Function in People Who Are at High Risk of Developing Contrast-induced Nephropathy1
Not AvailableUnknown StatusTreatmentEsophagus, Barrett / Reflux, Gastroesophageal1
Not AvailableWithdrawnScreeningPatients Undergoing Screening or Surveillance Colonoscopy1
Not AvailableWithdrawnTreatmentAltered Mental Status / AMS / HE / Hepatic Encephalopathy / Liver Cirrhosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
LiquidTopical50 mg/mL
LiquidTopical5 g/100g
Powder, for solutionIntraocular
LiquidOral525 mg/15mL
Powder, for solutionOral1 g/g
PowderOral100 %
Powder, for solutionHemodialysis
Kit; powder, for solution; tablet, delayed releaseOral
LiquidHemodialysis81.25 g
LiquidHemodialysis72 g
LiquidHemodialysis80.68 g
SolutionHemodialysis80.7 g
SolutionHemodialysis
SolutionHemodialysis81.3 g
LiquidHemodialysis
PowderHemodialysis1250 g
PowderHemodialysis720 g
Kit; powder, for solutionHemodialysis
Powder, for solutionHemodialysis750 g
Powder, for solutionHemodialysis900 g
Granule, effervescentOral
Granule, effervescentOral1.02 g/5g
Granule, effervescentOral1.8 g
Granule, effervescentOral269 mg
Kit; solutionIntraocular
LiquidIntravenous
SuppositoryRectal
Powder, for solutionNasogastric
Kit
PowderNasal
SolutionNasal
PowderOral2.6 g/2.6g
LiquidOral25 mg/mL
PowderTopical165 g/300g
PowderHemodialysis6 kg
Powder, for solutionHemodialysis650 g
PowderOral1000 mg/g
GranuleOral
Kit; solutionIntraocular; Irrigation
Injection, solutionIntravenous.2 g/5mL
Tablet, effervescentOral
SolutionOral
Capsule, gelatin coatedOral
Powder, for suspensionOral
Liquid; mouthwashOral
SolutionIntravenous
Powder, for solutionOral
SolutionHemodialysis; Intravenous
LiquidOral
Powder, for solutionNasal
KitNasal
TabletOral
InjectionIntravenous84 mg/mL
InjectionParenteral84 mg/mL
Injection, solutionIntravenous42 mg/mL
Injection, solutionIntravenous44.6 meq/50mL
Injection, solutionIntravenous75 mg/mL
Injection, solutionIntravenous84 mg/mL
PowderOral; Topical100 %
SolutionIntravenous42 mg/mL
SolutionParenteral84 mg/mL
TabletOral650 mg/1
Tablet, orally disintegratingOral650 mg/1
TabletOral648 mg/1
TabletOral324 mg/1
TabletOral325 mg/1
LiquidIntravenous50 mg
SolutionIntravenous5 g
PowderOral1 g/g
PowderOral2.616 g/2.616g
Powder, for solutionHemodialysis672 g
LiquidIntravenous42 mg
LiquidIntravenous75 mg
LiquidIntravenous84 mg
SolutionIntravenous75 mg
SolutionIntravenous4.2 g
SolutionIntravenous42 mg
SolutionIntravenous84 mg
TabletOral300 mg
TabletOral600 mg
PowderHemodialysis650 g
PowderHemodialysis
Powder, for solutionHemodialysis1100 g
Powder, for solutionHemodialysis760 g
CapsuleOral
PowderOral
KitOral
CreamTopical50 mg/g
Powder, for solutionNasogastric; Oral
Granule, for solutionNasal
Prices
Unit descriptionCostUnit
Golytely 236 gm Solution28.0USD bottle
Colyte 240 gm Solution26.0USD bottle
Golytely 227.1 gm Solution Packet21.85USD packet
Colyte-Flavored 240 gm Solution18.17USD bottle
Elliotts b solution ampule4.71USD ml
Sodium bicarb 4.2% vial1.45USD ml
Neut 4% vial0.92USD ml
Bss plus eye solution0.2USD ml
Sodium bicarb 650 mg tablet0.07USD tablet
Antacid 650 mg tablet0.05USD tablet
Antacid 325 mg tablet0.04USD tablet
Sodium bicarb 325 mg tablet0.04USD tablet
Sodium bicarb 7.5% vial0.04USD ml
Sodium bicarbonate powder0.03USD g
Sodium bicarb 8.4% vial0.02USD ml
Sodium bicarbonate 5% inj0.02USD ml
Colyte with flavor packets0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6489346No1996-07-162016-07-16Us
US6699885No1996-07-162016-07-16Us
USRE45198No1996-07-162016-07-16Us
US6645988No1996-07-162016-07-16Us
US7399772No1996-07-162016-07-16Us
US5945449No1997-10-312017-10-31Us
US7300674No2003-03-042023-03-04Us
US7291324No2002-10-222022-10-22Us
US5840737No1996-07-152016-07-15Us
US6780882No1996-07-152016-07-15Us
US7084130No2001-11-292021-11-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Decomposes around 50 °CNot Available
water solubility1E+005 mg/L (at 25 °C)MERCK INDEX (1996)
pKa6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility764.0 mg/mLALOGPS
logP-0.06ALOGPS
logP0.25ChemAxon
logS0.96ALOGPS
pKa (Strongest Acidic)6.05ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity20.34 m3·mol-1ChemAxon
Polarizability3.86 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9292
Blood Brain Barrier+0.936
Caco-2 permeable-0.5321
P-glycoprotein substrateNon-substrate0.8785
P-glycoprotein inhibitor INon-inhibitor0.9903
P-glycoprotein inhibitor IINon-inhibitor0.9931
Renal organic cation transporterNon-inhibitor0.9563
CYP450 2C9 substrateNon-substrate0.8326
CYP450 2D6 substrateNon-substrate0.9017
CYP450 3A4 substrateNon-substrate0.8144
CYP450 1A2 substrateNon-inhibitor0.9053
CYP450 2C9 inhibitorNon-inhibitor0.9337
CYP450 2D6 inhibitorNon-inhibitor0.9401
CYP450 2C19 inhibitorNon-inhibitor0.9461
CYP450 3A4 inhibitorNon-inhibitor0.9774
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9911
Ames testNon AMES toxic0.9285
CarcinogenicityNon-carcinogens0.5181
BiodegradationReady biodegradable0.9636
Rat acute toxicity1.9204 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9596
hERG inhibition (predictor II)Non-inhibitor0.9866
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic carbonic acids and derivatives
Sub Class
Organic carbonic acids
Direct Parent
Organic carbonic acids
Alternative Parents
Carbonate salts / Organic sodium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Carbonate salt / Carbonic acid / Organic alkali metal salt / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic sodium salt / Organic salt / Organooxygen compound / Carbonyl group
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
one-carbon compound, organic sodium salt (CHEBI:32139)

Targets

1. Hydrogen ions
Kind
Small molecule
Organism
Not Available
Pharmacological action
Yes
Actions
Neutralizer
References
  1. Nudel DB, Peterson BJ, Buckley BJ, Kaplan NA, Weinhaouse E, Gootman N: Comparative effects of bicarbonate and dichloroacetate in newborn swine with hypoxic lactic acidosis. Dev Pharmacol Ther. 1990;15(2):86-93. [PubMed:1964114]
  2. Roderick P, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001890. [PubMed:17253467]
  3. Balali-Mood M, Balali-Mood K: Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med. 2008 Jan;11(1):65-89. [PubMed:18154426]
  4. Vaughan-Jones RD, Spitzer KW: Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol. 2002;80(5):579-96. [PubMed:12440699]
  5. Levraut J, Giunti C, Ciebiera JP, de Sousa G, Ramhani R, Payan P, Grimaud D: Initial effect of sodium bicarbonate on intracellular pH depends on the extracellular nonbicarbonate buffering capacity. Crit Care Med. 2001 May;29(5):1033-9. [PubMed:11378618]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electrogenic sodium/bicarbonate cotransporter with a Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3. May regulate bicarbonate influx/efflux at the basolateral membrane of cells and regulate in...
Gene Name
SLC4A4
Uniprot ID
Q9Y6R1
Uniprot Name
Electrogenic sodium bicarbonate cotransporter 1
Molecular Weight
121459.38 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electroneutral sodium- and bicarbonate-dependent cotransporter with a Na(+):HCO3(-) 1:1 stoichiometry. Regulates intracellular pH and may play a role in bicarbonate salvage in secretory epithelia. ...
Gene Name
SLC4A7
Uniprot ID
Q9Y6M7
Uniprot Name
Sodium bicarbonate cotransporter 3
Molecular Weight
136042.595 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Mediates electroneutral sodium- and carbonate-dependent chloride-HCO3(-) exchange with a Na(+):HCO3(-) stoichiometry of 2:1. Plays a major role in pH regulation in neurons. May be involved in cell ...
Gene Name
SLC4A8
Uniprot ID
Q2Y0W8
Uniprot Name
Electroneutral sodium bicarbonate exchanger 1
Molecular Weight
122936.66 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Mediates sodium- and bicarbonate-dependent electrogenic sodium bicarbonate cotransport, with a Na(+):HCO3(-) stoichiometry of 2:1. May have a housekeeping function in regulating the pH of tissues i...
Gene Name
SLC4A5
Uniprot ID
Q9BY07
Uniprot Name
Electrogenic sodium bicarbonate cotransporter 4
Molecular Weight
126254.04 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electrogenic sodium/bicarbonate cotransporter in exchange for intracellular chloride. Plays an important role in regulating intracellular pH (By similarity).
Gene Name
SLC4A10
Uniprot ID
Q6U841
Uniprot Name
Sodium-driven chloride bicarbonate exchanger
Molecular Weight
125945.115 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]

Drug created on July 08, 2007 10:59 / Updated on November 14, 2017 08:09